5.13
-0.06 (-1.16%)
| Previous Close | 5.19 |
| Open | 5.16 |
| Volume | 577 |
| Avg. Volume (3M) | 9,210 |
| Market Cap | 22,273,024 |
| Price / Sales | 0.650 |
| Price / Book | 3.00 |
| 52 Weeks Range | |
| Earnings Date | 16 Apr 2025 - 23 Apr 2025 |
| Profit Margin | -80.28% |
| Operating Margin (TTM) | -202.50% |
| Diluted EPS (TTM) | -9.66 |
| Quarterly Revenue Growth (YOY) | -34.70% |
| Total Debt/Equity (MRQ) | 242.97% |
| Current Ratio (MRQ) | 0.460 |
| Operating Cash Flow (TTM) | -397.75 M |
| Levered Free Cash Flow (TTM) | -622.99 M |
| Return on Assets (TTM) | -5.20% |
| Return on Equity (TTM) | -38.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Care Facilities (US) | Mixed | Mixed |
| Medical Care Facilities (Global) | Mixed | Mixed | |
| Stock | Concord Medical Services Holdin | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.00 |
|
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions. |
|
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| % Held by Insiders | 18.00% |
| % Held by Institutions | 0.03% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Apr 2025 | Announcement | Concord Medical Files Annual Report on Form 20-F for Fiscal 2024 |
| 5Y Average Dividend Yield | 0.00% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 23 Dec 2015 | - | 29 Jan 2016 | 0.98 Cash |
| 05 Aug 2014 | - | 26 Sep 2014 | 0.89 Cash |
| 16 Jan 2014 | - | 30 Jan 2014 | 0.71 Cash |
| 29 Aug 2011 | - | 30 Sep 2011 | 0.17 Cash |
| 29 Aug 2011 | - | 30 Sep 2011 | 0.18 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2016 | 0.980 | 1 | 2.13 |
| 2014 | 1.60 | 2 | 2.50 |
| 2011 | 0.350 | 2 | 1.23 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |